UK markets close in 5 hours 7 minutes

Neurocrine Biosciences, Inc. (0K6R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
75.44+0.88 (+1.18%)
As of 06:21PM GMT. Market open.

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600

Full-time employees917

Key executives

NameTitlePayExercisedYear born
Dr. Kevin C. Gorman Ph.D.CEO & Director1.38MN/A1958
Mr. Matthew C. AbernethyChief Financial Officer781.04k549.13k1980
Mr. Kyle W. GanoChief Bus. Devel. and Strategy Officer711.72kN/A1973
Mr. Eric S. BenevichChief Commercial Officer748.83k1.25M1965
Dr. Eiry Wyn RobertsChief Medical Officer847.94k260.95k1964
Dr. Dimitri E. GrigoriadisChief Research OfficerN/AN/A1958
Dr. Jude Onyia Ph.D.Chief Scientific OfficerN/AN/AN/A
Jane SorensenHead of Investor RelationsN/AN/AN/A
Mr. Darin M. LippoldtChief Legal Officer & Corp. Sec.N/AN/A1966
Ms. Julie S. CookeChief HR OfficerN/AN/A1966
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Corporate governance

Neurocrine Biosciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 4; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.